- Research article
- Open Access
- Open Peer Review
Variation in geographic access to chemotherapy by definitions of providers and service locations: a population-based observational study
BMC Health Services Researchvolume 16, Article number: 274 (2016)
An aging population, with its associated rise in cancer incidence and strain on the oncology workforce, will continue to motivate patients, healthcare providers and policy makers to better understand the existing and growing challenges of access to chemotherapy. Administrative data, and SEER-Medicare data in particular, have been used to assess patterns of healthcare utilization because of its rich information regarding patients, their treatments, and their providers. To create measures of geographic access to chemotherapy, patients and oncologists must first be identified. Others have noted that identifying chemotherapy providers from Medicare claims is not always straightforward, as providers may report multiple or incorrect specialties and/or practice in multiple locations. Although previous studies have found that specialty codes alone fail to identify all oncologists, none have assessed whether various methods of identifying chemotherapy providers and their locations affect estimates of geographic access to care.
SEER-Medicare data was used to identify patients, physicians, and chemotherapy use in this population-based observational study. We compared two measures of geographic access to chemotherapy, local area density and distance to nearest provider, across two definitions of chemotherapy provider (identified by specialty codes or billing codes) and two definitions of chemotherapy service location (where chemotherapy services were proven to be or possibly available) using descriptive statistics. Access measures were mapped for three representative registries.
In our sample, 57.2 % of physicians who submitted chemotherapy claims reported a specialty of hematology/oncology or medical oncology. These physicians were associated with 91.0 % of the chemotherapy claims. When providers were identified through billing codes instead of specialty codes, an additional 50.0 % of beneficiaries (from 23.8 % to 35.7 %) resided in the same ZIP code as a chemotherapy provider. Beneficiaries were also 1.3 times closer to a provider, in terms of driving time. Our access measures did not differ significantly across definitions of service location.
Measures of geographic access to care were sensitive to definitions of chemotherapy providers; far more providers were identified through billing codes than specialty codes. They were not sensitive to definitions of service locations, as providers, regardless of how they are identified, generally provided chemotherapy at each of their practice locations.
Patients who live in areas where chemotherapy providers are scarce must travel extended distances to receive treatment [1–3]. Research suggests that some patients who may benefit from chemotherapy remain untreated because of where they live [1, 2, 4–6]. Thus measures of geographic access to chemotherapy have been constructed to better understand these potential barriers to treatment. The two most common geographic access to care measures include local area density and distance to the nearest chemotherapy provider [1, 7–9]. To construct these measures, researchers must accurately identify chemotherapy providers and their service locations. Failure to account for all types of service locations can bias estimates of geographic access to chemotherapy. For example, in a recent study, the median driving time to the nearest chemotherapy provider decreased from 51.6 to 19.2 min when visiting consulting clinics were included .
Measures of geographic access to chemotherapy are often created using Medicare claims because they offer detailed information regarding treatments, providers and patients . Unfortunately, even with this information, creating measures of geographic access to chemotherapy is not completely straightforward, as noted in the literature [12, 13]. Baldwin et al. state that researchers may need to distinguish between those who claim to be oncologists (through specialty codes) and those who do the work of an oncologist (through billing codes) when identifying chemotherapy providers . They also acknowledge that identifying service locations is not trivial, as providers can and do practice at more than one location . Should researchers assume that chemotherapy can only be provided at locations where it has been in the past, i.e. “proven” service locations? Or is reasonable to assume that chemotherapy may be available at each practice location, i.e. “possible” service locations?
Although the challenges of identifying providers and service locations have been previously noted, no research has quantified the effect of these various definitions on measures of geographic access to care. As there exists no standard protocol in how to define providers and locations, the definitions vary across studies. Some have used specialty codes to identify providers [14–16]. One paper used billing codes  and another used both billing and specialty codes . Another strategy has been to supplement Medicare data with outside sources, such as the American Medical Association (AMA) physician masterfile or the Area Health Resource Files [1, 2, 4, 18–20]. Although doing so has been shown to capture more oncologists [12, 13], our objective was slightly different. We were interested in how various methods of identifying chemotherapy providers and locations impacted the two most commonly used measures of geographic access to chemotherapy: local area density and distance to nearest provider.
We used retrospective data from the 2006 Surveillance, Epidemiology and End Results (SEER)-Medicare database. As a network of population-based cancer registries, SEER currently covers approximately 28 % of the U.S. population . SEER-Medicare data is often used to study geographic access to chemotherapy for cancer patients because it offers detailed patient and provider information [11, 22].
Beneficiary ZIP code was abstracted from the SEER Patient Entitlement and Diagnosis Summary File (PEDSF) file. Medicare claims were used to identify chemotherapy use, provider specialty, and service location. We limited our analysis to the Carrier claims because only these report both provider specialty and location information. Driving times were calculated by Microsoft MapPoint. We chose driving-time distance instead of a straight Euclidian distance, i.e. “as the crow flies,” to account for topology (e.g. mountains, lakes, etc.) and their associated road structures, along with variations in travel time due to speed limits.
To create our study cohort, we excluded unmatched ZIP codes. In 2006 35,206 Medicare beneficiaries across the 18 SEER registries were diagnosed with lung cancer. After excluding the beneficiaries for whom distances could not be calculated (N = 46) and whose residence ZIP code did not map onto a SEER registry according to MapPoint (N = 764), our final sample included 34,396 beneficiaries and their claims. Our methodology, which consisted of 2x2 possible ways of identifying providers and locations, is visually depicted (Fig. 1).
Identifying chemotherapy providers
When we identified chemotherapy providers by specialty codes, individuals reporting a Hematology/Oncology (83) or Medical Oncology (90) specialty code on any claim were included. This would also apply to providers who reported multiple specialties among their claims. With this methodology, it is possible for an individual to not be labeled a chemotherapy provider even if they repeatedly billed for chemotherapy because an oncology specialty code was never reported. Chemotherapy providers were also identified through chemotherapy-related billing codes, Healthcare Common Procedure Coding System (HCPCS) codes and International Classification of Diseases, Clinical Modification diagnosis codes (ICD9-CM DX), provided by the SEER-Medicare program  and reported in Table 1. Hence an individual was considered a chemotherapy provider if they billed for chemotherapy-related services. With this method, it was possible for individuals who reported an oncology specialty code on claims to not be labeled an oncologist because none of their claims were chemotherapy related.
Identifying chemotherapy service locations
Chemotherapy service locations were defined as either “possible” or “proven.” Proven service locations included only the practice locations from which providers billed Medicare for chemotherapy-related services. Possible service locations included all of a provider’s practice locations, regardless of whether a particular location ever filed a chemotherapy-related claim, under the assumption that each location could provide chemotherapy. The first method provides then a lower-bound estimate of service locations and the second an upper bound.
Geographic access to chemotherapy measures
For a total of four possible specifications (specialty codes to identify provider and their proven service locations; specialty codes to identify provider and their possible service locations; billing codes to identify providers and their proven service locations; and billing codes to identify providers and their possible service locations), we estimated the two most commonly used measures of geographic access to chemotherapy: local area density and distance to nearest chemotherapy provider [24–26]. Measures of local area density form the basis for the increasingly popular floating catchment area methods and kernel density estimation methods . In this paper, local area density was calculated by summing the number of unique chemotherapy providers within a 20-min driving-time radius from each beneficiary’s ZIP code centroid. Distance to nearest oncologist was calculated by the driving-time distance, in minutes, between centroids. If the beneficiary resided in the same ZIP code as the nearest chemotherapy service location, the distance between the two was set to zero. It is important to note that these measure potential access to chemotherapy and not actual utilization.
We calculated descriptive statistics and assessed differences between the estimates with Student’s t-tests. All analyses were conducted using SAS Software, version 9.3. Maps were created using Microsoft MapPoint 2013 for three representative SEER registries (Iowa, Connecticut and New Jersey) which vary in their degree of rurality.
Among the 216,438 unique providers with usable ZIP code information who cared for our study population in any capacity, 4,424 reported an oncology specialty code and 6,253 billed Medicare for a chemotherapy-related service. These 4,424 providers, as defined by specialty codes, provided chemotherapy in 5,076 locations (proven service locations) and practiced in a total of 5,157 locations (possible service locations). The 6,253 providers, as defined by chemotherapy billing codes, provided chemotherapy in 6,722 locations and practiced in 8,101 locations. Thus, on average, providers administered chemotherapy in 1.08-1.30 locations, depending on how provider and service locations were defined.
Specialty codes and chemotherapy-related claims
Of the 6,253 unique providers who billed for chemotherapy-related services, 541 (8.7 %) reported more than one specialty and none were missing. The top four specialties reported by unique physicians included hematology/oncology (42.1 %), medical oncology (15.1 %), urology (9.8 %), and internal medicine (6.0 %). The two specialties of hematology/oncology and medical oncology comprised 57.2 % of the physicians.
However when we categorized the chemotherapy-related claims by specialty, we found that 91.0 % of the claims reported either a specialty of hematology/oncology (65.7 %) or medical oncology (25.3 %). The two next most commonly reported specialty on the claims were hematology (3.1 %) and internal medicine (2.9 %). This would indicate that, although self-reported oncologists are not the only ones administering chemotherapy, they are the ones who provide most of the observed chemotherapy-related services. We conducted an ad hoc analysis to confirm. Of physicians who reported only one specialty (N = 5,712), each hematologist/oncologist (medical oncologist) submitted on average 380.1 (388.8) chemotherapy claims during the study period. In contrast, each internist and urologist submitted on average 54.2, 10.0 claims, respectively.
Geographic measures of access to chemotherapy
After characterizing the specialties associated with the claims, we estimated the two geographic access to care measures using the various provider and location definitions. We discuss results only for the proven locations, as access measures did not differ statistically across service location definitions.
Specialty codes to identify chemotherapy provider
Identifying chemotherapy providers by specialty codes, we found on average 21.1 (SD = 29.8) providers within 20 min of a beneficiary, with a median value of 8 (Table 2). Almost 75 % of beneficiaries had access to at least one chemotherapy provider within 20 min. The driving-time distance to the nearest chemotherapy provider was on average 16.1 min (SD = 20.3). Half of the sample was within 10.7 min of a provider and patients in the 95th percentile would need to drive 51.9 min to get to the nearest provider. These driving-time estimates are skewed towards zero because we are unable to assess distances within the same ZIP code. Thus, we also report the percent of patients that resided in the same ZIP code as a chemotherapy provider (Table 3). Overall, 23.8 % of beneficiaries resided in the same ZIP code as a chemotherapy provider, when defined by specialty code.
Billing codes to identify chemotherapy provider
We identified a substantially larger number of chemotherapy providers through chemotherapy billing codes. With this definition, beneficiaries had on average 41.9 (SD = 52.3) providers within 20 min, 2.0 times more than when identified by specialty codes (p-value < 0.0001). Driving time also decreased when identifying chemotherapy provider through billing codes. With this definition, beneficiaries were on average 12.2 (SD = 16.6) minutes away from a chemotherapy provider, 1.3 times closer than when identified by specialty codes (p-value < 0.0001). Over three quarters (79.4 %) had access to at least one chemotherapy provider within 20 min and over a third (35.7 %) resided in the same ZIP code as a chemotherapy provider, a 50.0 % increase compared to identifying providers through specialty code (p < 0.0001).
Geographic variation in access to chemotherapy
Geographic access to chemotherapy (defined here as any provider practicing in their proven locations within 20 min of a beneficiary) was mapped for three representative SEER registries in Fig. 2. Panel A identified chemotherapy providers through specialty codes and panel B through chemotherapy billing codes. Brownish-grey areas signify that no beneficiary was diagnosed with lung-cancer in that ZIP code during the study period. Regardless of which method was used to identify providers, fewer Iowa beneficiaries were within a 20-min driving radius of a chemotherapy provider than beneficiaries residing in New Jersey or Connecticut. Similarly, Iowa beneficiaries were less likely to reside in the same ZIP code as a chemotherapy provider than beneficiaries residing in Connecticut or New Jersey: 17.9 % when identified by specialty code and proven locations in Iowa versus 23.5 % in Connecticut and 26.9 % in New Jersey (Table 3). When identified by chemotherapy billing codes, 35.0 % of Iowa beneficiaries resided in the same ZIP code as a provider, a substantial and statistically significant increase over identification by specialty code (p < 0.0001). Indeed, this rate was similar to the rate in Connecticut (36.0 %), although still less than New Jersey (43.5 %).
Access to treatments for cancer, whether geographic or financial, continues to be of interest to policy makers and researchers [1, 10, 27, 28]. However, previous papers estimating geographic access to chemotherapy using Medicare claims have not assessed whether their results are sensitive to how chemotherapy providers and service locations are identified. We found that the method of identifying who, but not where, chemotherapy is provided affected our two measures of geographic access to chemotherapy.
In our analysis, a number of specialties in addition to hematology/oncology and medical oncology billed Medicare for chemotherapy-related services, with 42.8 % of the providers associated with chemotherapy claims reporting a specialty other than hematology/oncology or medical oncology. Even so, physicians who reported a specialty of hematology/oncology or medical oncology provided the vast majority of the chemotherapy services (91.0 % of the claims).
When we identified chemotherapy providers through chemotherapy billing codes rather than specialty codes, we found that average driving-time distances for beneficiaries decreased by almost a quarter and the average number of providers within 20 min increased two-fold. An additional 50 % of beneficiaries resided in the same ZIP code as a chemotherapy provider when providers were identified using billing codes instead of specialty codes (35.7 % versus 23.8 %). This suggests that a number of oncologists might be reporting a specialty other than hematology/oncology and medical oncology. There are a number of reasons why this may be the case. First, all oncologists are trained in internal medicine before they specialize in oncology. Also, specialty certification is independent of maintaining one’s license, the former not mandatory for practice. Finally, accuracy in specialty code reporting is not required for reimbursement. Any/all of these factors could cause underreporting of oncology specialty codes.
The increase in geographic access to chemotherapy when providers are identified through chemotherapy billing codes instead of specialty codes is consistent with the literature showing underreporting of oncology specialty on Medicare claims [12, 13]. This does not necessarily imply that all of the providers associated with chemotherapy claims were indeed oncologists. It may also be the case that other specialties truly are providing chemotherapy. One could concoct a scenario where chemotherapy was provided by a non-oncologist under extenuating circumstances, but to which future provision of chemotherapy from that same provider is unlikely. Thus there is an additional dimension which has yet to be explored in the literature - whether past provision of chemotherapy is indicative of future access.
Although our measures of geographic access to chemotherapy varied substantially by how we identified chemotherapy providers, there was no statistical difference across service location definitions. This was due to the fact that chemotherapy providers in this sample in general provided chemotherapy at each location in which they practiced.
There are limitations to our study. First, we only utilize Medicare claims. Inclusion of additional data would affect the magnitude of our estimates, as others have found . Unfortunately, NCI no longer releases unencrypted Unique Physician Identification Number (UPIN) or National Provider Identifier (NPI), rendering these linkages impossible. Our contribution to the literature, however, is not providing “the” estimate of geographic access to chemotherapy but instead assessing how definitions of “who” and “where” affect these estimates, something that others have noted might be an issue but never quantified . In addition, we only include Carrier claims, which comprise about 75 % of chemotherapy claims. However the outpatient files do not include specialty information.
Another limitation is that we only include lung cancer patients and their providers. However, unless lung cancer patients are systematically avoiding some chemotherapy providers by how the providers report their specialty, our estimates of geographic access to care across definitions of providers and locations will not be biased. If some oncologists are sufficiently specialized (e.g. at an NCI-designated comprehensive cancer center) such that they never treat lung cancer patients, then they would not be captured in our analysis. However, these sorts of locations would also likely have oncologists that do specialize in lung cancer. Although absolute measures of access would not be accurate, relative measures across the various definitions, our outcome of interest, would still be valid. We also only include a single year of data. In doing so we may not capture physicians and their service locations if they bill Medicare less than once a year. Finally, our distances are calculated between ZIP code centroids. We acknowledge that distances between centroids are not as accurate as mailing addresses, and that driving times within a centroid is not zero. In addition, for ZIP codes that cover a large geographic area, the next closest ZIP code may be more than 20 min away. If there are no chemotherapy providers in the same ZIP code as the patient, that area would be considered as not having access to chemotherapy as we have defined it. ZIP codes can also change over time, increasing the complexity of geographic analyses.
Improving geographic access to care and reducing health disparities have been of interest to healthcare providers and policy makers for some time and will continue to be so. Oncology services in particular are estimated to experience shortages in the coming years due to an aging population and insufficient growth in the physician workforce . The effect is likely heterogeneous, as demographic compositions vary across areas and over time due to both aging in place and retirement migration. To the extent that measures of geographic access to care affect health policy, it is imperative that these measures be accurate. Our study suggests that measures of access to chemotherapy are more sensitive to how one identifies chemotherapy providers than service locations. Given that others have shown underreporting in specialty codes, perhaps both methods of identifying providers ought to be used to bound estimates of measures of geographic access to care.
HCPCS, Healthcare Common Procedure Coding System; ICD9-CM DX, International Classification of Diseases – 9th edition, Clinical Modification, diagnosis code; NCI, National Cancer Institute; NPI, National Provider Identifier; PEDSF, Patient Entitlement and Diagnosis Summary File; SD, standard deviation; SEER, Surveillance, Epidemiology and End Results; UPIN, Unique Physician Identification Number; ZIP, Zone Improvement Plan
Onega T, Duell EJ, Shi X, Wang D, Demidenko E, Goodman D. Geographic access to cancer care in the U.S. Cancer. 2008;112(4):909–18.
Baldwin LM, Cai Y, Larson EH, Dobie SA, Wright GE, Goodman DC, et al. Access to cancer services for rural colorectal cancer patients. J Rural Health. 2008;24(4):390–9.
Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A, et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst. 2006;98(3):172–80.
Lin CC, Virgo KS. Association between the availability of medical oncologists and initiation of chemotherapy for patients with stage III colon cancer. J Oncol Pract. 2013;9(1):27–33.
Earle CC, Neumann PJ, Gelber RD, Weinstein MC, Weeks JC. Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol. 2002;20(7):1786–92.
Earle CC, Venditti LN, Neumann PJ, Gelber RD, Weinstein MC, Potosky AL, et al. Who gets chemotherapy for metastatic lung cancer? Chest. 2000;117(5):1239–46.
Holmes JA, Carpenter WR, Wu Y, Hendrix LH, Peacock S, Massing M, et al. Impact of distance to a urologist on early diagnosis of prostate cancer among black and white patients. J Urol. 2012;187(3):883–8.
Shea AM, Curtis LH, Hammill BG, DiMartino LD, Abernethy AP, Schulman KA. Association between the Medicare Modernization Act of 2003 and patient wait times and travel distance for chemotherapy. JAMA. 2008;300(2):189–96.
Wheeler SB, Carpenter WR, Peppercorn J, Schenck AP, Weinberger M, Biddle AK. Structural/organizational characteristics of health services partly explain racial variation in timeliness of radiation therapy among elderly breast cancer patients. Breast Cancer Res Treat. 2012;133(1):333–45.
Tracy R, Nam I, Gruca TS. The influence of visiting consultant clinics on measures of access to cancer care: evidence from the state of Iowa. Health Serv Res. 2013;48(5):1719–29.
Warren JL, Harlan LC, Fahey A, Virnig BA, Freeman JL, Klabunde CN, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40(8 Suppl):IV-55–61.
Baldwin LM, Adamache W, Klabunde CN, Kenward K, Dahlman C, LW J. Linking physician characteristics and medicare claims data: issues in data availability, quality, and measurement. Med Care. 2002;40(8 Suppl):IV-82–95.
Pollack LA, Adamache W, Eheman CR, Ryerson AB, Richardson LC. Enhancement of identifying cancer specialists through the linkage of Medicare claims to additional sources of physician specialty. Health Serv Res. 2009;44(2 Pt 1):562–76.
Wang J, Kuo YF, Freeman J, Goodwin JS. Increasing access to medical oncology consultation in older patients with stage II-IIIA non-small-cell lung cancer. Med Oncol. 2008;25(2):125–32.
Keating NL, Landrum MB, Ayanian JZ, Winer EP, Guadagnoli E. Consultation with a medical oncologist before surgery and type of surgery among elderly women with early-stage breast cancer. J Clin Oncol. 2003;21(24):4532–9.
Silber JH, Rosenbaum PR, Polsky D, Ross RN, Even-Shoshan O, Schwartz JS, et al. Does ovarian cancer treatment and survival differ by the specialty providing chemotherapy? J Clin Oncol. 2007;25(10):1169–75.
Wheeler SB, Carpenter WR, Peppercorn J, Schenck AP, Weinberger M, Biddle AK. Predictors of timing of adjuvant chemotherapy in older women with hormone receptor-negative, stages II-III breast cancer. Breast Cancer Res Treat. 2012;131(1):207–16.
Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ. Factors related to underuse of surveillance mammography among breast cancer survivors. J Clin Oncol. 2006;24(1):85–94.
Simpson DR, Martinez ME, Gupta S, Hattangadi-Gluth J, Mell LK, Heestand G, et al. Racial disparity in consultation, treatment, and the impact on survival in metastatic colorectal cancer. J Natl Cancer Inst. 2013;105(23):1814–20.
Onukwugha E, Mullins CD, Hsu VD, Seal B, Hussain A. Effect of urologists and medical oncologists on treatment of elderly men with stage IV prostate cancer. Urology. 2011;77(5):1088–95.
National Cancer Institute. Overview of the SEER Program. http://seer.cancer.gov/about/overview.html. Accessed July 1, 2015.
Cooper GS, Yuan Z, Stange KC, Amini SB, Dennis LK, Rimm AA. The utility of Medicare claims data for measuring cancer stage. Med Care. 1999;37(7):706–11.
National Cancer Institute. Procedure Codes for SEER-Medicare Analyses. http://healthcaredelivery.cancer.gov/seermedicare/considerations/procedure_codes.html. Accessed April 24, 2016.
Higgs G. A literature review of the use of GIS-based measures of access to health care services. Health Serv Outcomes Res Methodol. 2004;5(2):119–39.
Higgs G. The role of GIS for health utilization studies: literature review. Health Serv Outcomes Res Methodol. 2009;9(2):84–99.
Neutens T. Accessibility, equity and health care: review and research directions for transport geographers. J Transp Geogr. 2015;43:14–27.
Berry SR, Evans WK, Strevel EL, Bell CM. Variation and consternation: access to unfunded cancer drugs in Canada. J Oncol Pract. 2012;8(1):35–9.
Ward MM, Ullrich F, Matthews K, Rushton G, Tracy R, Bajorin DF, et al. Access to chemotherapy services by availability of local and visiting oncologists. J Oncol Pract. 2014;10(1):26–31.
Erikson C, Salsberg E, Forte G, Bruinooge S, Goldstein M. Future supply and demand for oncologists: challenges to assuring access to oncology services. J Oncol Pract. 2007;3(2):79–86.
This study used the linked SEER-Medicare database. The interpretation and reporting of these data are the sole responsibility of the authors. The authors acknowledge the efforts of the Applied Research Program, NCI; the Office of Research, Development and Information, CMS; Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database.
This work was supported by the Holden Comprehensive Cancer Center’s Population Science Pilot Award through the National Cancer Institute of the National Institutes of Health under Award Number P30CA086862.
Availability of data and materials
The data supporting the conclusions of this article are not available publically. The raw data can be obtained from the National Cancer Institute (NCI) for research purposes. Project-specific approval must be granted before SEER-Medicare data is released to investigators. In addition, some variables are encrypted or restricted (e.g. patient and physician ZIP code). Additional approval processes from both NCI and the individual cancer registries are required to obtain these data. Information regarding the process of obtaining the data can be found on their website (http://healthcaredelivery.cancer.gov/seermedicare/obtain/). Per the data use agreement, manuscripts must also be reviewed by the SEER-Medicare contact (Information Management Services, Inc.) prior to submission to ensure the topic matched the data use agreement, along with patient and provider confidentiality. Any intention to map cancer incidence, treatment or survival must also be declared in the proposal. Presentation of data for individual registries must be approved by the principal investigator for that registry.
Each author has participated actively, substantively, and sufficiently in this study. MS and MN conceived of the study. CC, YT, and MN created the study sample and conducted analyses. MS and MN led the writing of the manuscript. All authors participated in its design, and helped interpret the results. MS, CC, MN, TH, TA, JB revised the manuscript for important intellectual content. All authors have read and approved the final manuscript.
Dr. Halfdanarson has held a consulting or advisory role with Novartis and has received research funding from Boston Biomedical and Temkira to his institution. Dr. Abu Hejleh has received honoraria from Qessential Medical Market Research and research funding from Novartis, Lilly, Genentech, and Merck to his institution. None of these entities supported this work or influenced the results and conclusions in any way. For the remaining authors no competing interests were declared.
Consent for publication
Ethics approval and consent to participate
The University of Iowa Institutional Review Board (IRB) approved this study and granted a full waiver of Health Insurance Portability and Accountability Act (HIPAA) authorization. A SEER-Medicare data use agreement was approved by the National Cancer Institute (NCI) for this project. The manuscript and the maps presented have been reviewed and approved by NCI and the Principal Investigators of the Connecticut, Iowa, and New Jersey SEER registries, to protect patient and physician confidentiality and to ensure compliance with the data use agreement.